Lundbeck (OTCMKTS:HLUYY) – Analysts at Jefferies Group lifted their Q2 2018 earnings estimates for Lundbeck in a research report issued to clients and investors on Thursday, May 17th. Jefferies Group analyst P. Welford now expects that the company will earn $0.93 per share for the quarter, up from their previous estimate of $0.76. Jefferies Group also issued estimates for Lundbeck’s Q3 2018 earnings at $0.90 EPS, Q4 2018 earnings at $0.66 EPS and FY2019 earnings at $3.38 EPS.
Several other analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Lundbeck from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 11th. DNB Markets downgraded shares of Lundbeck from a “buy” rating to a “sell” rating in a research note on Thursday, May 3rd.
Lundbeck Company Profile
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Denmark and internationally. Its products include Abilify Maintena, Brintellix/Trintellix, Cipralex/Lexapro, Northera, Onfi, Rexulti, Sabril, and Xenazine.
Receive News & Ratings for Lundbeck Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lundbeck and related companies with MarketBeat.com's FREE daily email newsletter.